Elevation Spine completed its Series B Preferred Stock financing, totaling $11 million.
Proceeds will support increased commercial production of Saber-C® spinal fusion technology, as well as development of future product extensions of the company’s Saber Technology platform of products.
Charles Gilbride, CEO of Elevation Spine, said, “This funding provides Elevation Spine with the capital to build out a full commercial team and expand the use of the Saber-C system. We will concurrently develop additional products utilizing Saber Technology to establish Saber as the leading platform technology in spinal fusions.”
Elevation Spine completed its Series B Preferred Stock financing, totaling $11 million.
Proceeds will support increased commercial production of Saber-C® spinal fusion technology, as well as development of future product extensions of the company’s Saber Technology platform of products.
Charles Gilbride, CEO of Elevation Spine, said, “This...
Elevation Spine completed its Series B Preferred Stock financing, totaling $11 million.
Proceeds will support increased commercial production of Saber-C® spinal fusion technology, as well as development of future product extensions of the company’s Saber Technology platform of products.
Charles Gilbride, CEO of Elevation Spine, said, “This funding provides Elevation Spine with the capital to build out a full commercial team and expand the use of the Saber-C system. We will concurrently develop additional products utilizing Saber Technology to establish Saber as the leading platform technology in spinal fusions.”
Copy to clipboard 
